# Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

> **NCT04592913** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 957 (actual)

## Conditions studied

- Gastrointestinal Neoplasms
- Esophagogastric Junction

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** FLOT chemotherapy

## Key facts

- **NCT ID:** NCT04592913
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-17
- **Primary completion:** 2024-12-20
- **Final completion:** 2027-09-27
- **Target enrollment:** 957 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04592913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04592913, "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04592913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*